Marshall Wace LLP Buys Shares of 87,913 biote Corp. (NASDAQ:BTMD)

Marshall Wace LLP acquired a new position in biote Corp. (NASDAQ:BTMD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 87,913 shares of the company's stock, valued at approximately $543,000. Marshall Wace LLP owned about 0.16% of biote at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Barclays PLC raised its holdings in biote by 52.3% in the third quarter. Barclays PLC now owns 77,196 shares of the company's stock worth $432,000 after purchasing an additional 26,510 shares in the last quarter. Sei Investments Co. raised its stake in shares of biote by 56.4% during the 4th quarter. Sei Investments Co. now owns 18,321 shares of the company's stock worth $113,000 after acquiring an additional 6,605 shares in the last quarter. Kanen Wealth Management LLC purchased a new stake in biote during the fourth quarter valued at approximately $1,791,000. Jane Street Group LLC boosted its stake in biote by 24.7% in the third quarter. Jane Street Group LLC now owns 16,873 shares of the company's stock valued at $94,000 after acquiring an additional 3,342 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in biote by 9.8% in the fourth quarter. Renaissance Technologies LLC now owns 178,994 shares of the company's stock worth $1,106,000 after purchasing an additional 16,017 shares during the last quarter. Institutional investors own 21.68% of the company's stock.

Insider Activity

In related news, major shareholder Guines Llc purchased 750,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were bought at an average cost of $3.22 per share, with a total value of $2,415,000.00. Following the transaction, the insider now owns 3,820,938 shares of the company's stock, valued at approximately $12,303,420.36. This trade represents a 24.42 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen Mark Cone acquired 38,104 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $3.88 per share, with a total value of $147,843.52. Following the acquisition, the director now owns 160,829 shares in the company, valued at approximately $624,016.52. This trade represents a 31.05 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 976,043 shares of company stock valued at $3,176,710 in the last ninety days. Insiders own 24.00% of the company's stock.

biote Stock Up 7.2 %

Shares of BTMD traded up $0.24 during trading hours on Thursday, reaching $3.58. 82,773 shares of the company traded hands, compared to its average volume of 192,891. The stock has a market capitalization of $195.86 million, a P/E ratio of 13.77 and a beta of 1.17. The business has a fifty day moving average price of $3.62 and a 200-day moving average price of $4.95. biote Corp. has a 12-month low of $3.04 and a 12-month high of $8.44.

biote (NASDAQ:BTMD - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.02. biote had a negative return on equity of 32.41% and a net margin of 5.20%. The firm had revenue of $48.99 million during the quarter, compared to analysts' expectations of $47.25 million. As a group, research analysts predict that biote Corp. will post 0.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Craig Hallum dropped their price target on biote from $12.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th.

biote Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.